Tempus AI
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of … Read more
Tempus AI (F3M) - Net Assets
Latest net assets as of June 2025: €309.56 Million EUR
Based on the latest financial reports, Tempus AI (F3M) has net assets worth €309.56 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.63 Billion) and total liabilities (€1.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €309.56 Million |
| % of Total Assets | 19.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Tempus AI - Net Assets Trend (2021–2024)
This chart illustrates how Tempus AI's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tempus AI (2021–2024)
The table below shows the annual net assets of Tempus AI from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €56.34 Million | +104.08% |
| 2023-12-31 | €-1.38 Billion | -22.42% |
| 2022-12-31 | €-1.13 Billion | -39.82% |
| 2021-12-31 | €-807.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tempus AI's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 134334800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.21 Billion | 3917.66% |
| Total Equity | €56.34 Million | 100.00% |
Tempus AI Competitors by Market Cap
The table below lists competitors of Tempus AI ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KT Corporation
NYSE:KT
|
$4.75 Billion |
|
Bank of Chengdu Co Ltd
SHG:601838
|
$4.76 Billion |
|
Showa Denko K.K
PINK:SHWDF
|
$4.76 Billion |
|
Bajaj Holdings & Investment Limited
NSE:BAJAJHLDNG
|
$4.77 Billion |
|
Phillips Edison & Co Inc
NASDAQ:PECO
|
$4.75 Billion |
|
IDFC First Bank Limited
NSE:IDFCFIRSTB
|
$4.74 Billion |
|
Suzlon Energy Limited
NSE:SUZLON
|
$4.74 Billion |
|
Sunwoda Electronic
SHE:300207
|
$4.74 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tempus AI's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,382,163,000 to 56,339,000, a change of 1,438,502,000.
- Net loss of 705,809,000 reduced equity.
- Dividend payments of 5,625,000 reduced retained earnings.
- Share repurchases of 2,250,000 reduced equity.
- New share issuances of 581,701,000 increased equity.
- Other factors increased equity by 1,570,485,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-705.81 Million | -1252.79% |
| Dividends Paid | €5.62 Million | -9.98% |
| Share Repurchases | €2.25 Million | -3.99% |
| Share Issuances | €581.70 Million | +1032.5% |
| Other Changes | €1.57 Billion | +2787.56% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Tempus AI's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 127.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-4.90 | €44.20 | x |
| 2022-12-31 | €-6.85 | €44.20 | x |
| 2023-12-31 | €-8.39 | €44.20 | x |
| 2024-12-31 | €0.35 | €44.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tempus AI utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1252.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -101.79%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 16.44x
- Recent ROE (-1252.79%) is below the historical average (-313.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -100.52% | 0.49x | 0.00x | €-178.44 Million |
| 2022 | 0.00% | -90.38% | 0.51x | 0.00x | €-176.91 Million |
| 2023 | 0.00% | -40.26% | 0.94x | 0.00x | €-75.90 Million |
| 2024 | -1252.79% | -101.79% | 0.75x | 16.44x | €-711.44 Million |
Industry Comparison
This section compares Tempus AI's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $2,161,712,407
- Average return on equity (ROE) among peers: -13.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tempus AI (F3M) | €309.56 Million | 0.00% | 4.25x | $4.75 Billion |
| Schrödinger, Inc. (43Z) | $557.09 Million | -18.02% | 0.36x | $631.00 Million |
| DACHA STRATEGIC (7DC) | $40.24 Million | 0.65% | 0.08x | $81.97 Million |
| ABL Diagnostics Société anonyme (9BK0) | $6.77 Million | 0.80% | 1.20x | $371.65K |
| Zhejiang Taimei Medical Technology Co., Ltd. (A2V) | $1.04 Billion | -33.28% | 0.39x | $47.71 Million |
| ASCOM HLDG NA SF 0,50 (AH2N) | $80.00 Million | 16.88% | 1.43x | $190.62 Million |
| DocCheck AG (AJ91) | $18.14 Million | 3.32% | 0.15x | $18.00 Million |
| EM Systems Co. Ltd (EMO) | $17.69 Billion | 7.87% | 0.33x | $74.55 Million |
| Pangenomic Health Inc. (LL3) | $2.24 Million | -118.14% | 0.15x | $4.82 Million |
| MeVis Medical Solutions AG (M3V) | $17.83 Million | 17.76% | 0.45x | $12.89 Million |